Biotech2k
Biotech Investor, AI-Driven Drug Discovery
Cogent Biosciences warrants an investment because its lead drug is up for approval in three indications, two with breakthrough therapy designation, and could reach $5-7 billion in peak sales. Management is good and the drug competes well; it was the top rival to Blueprint's. Early pipeline programs in KRAS, JAK and PI3K could add more potential if they repeat the success seen in KIT. x.comÂ
Cogent Biosciences looks insanely cheap on fear of a black box warning that is very unlikely. Its AST/ALT elevations were grade 1-3, lab-only events with no other lab findings, and in many approvals with similar safety data no black box was required. A warning could still happen, and the stock might rally anyway because the fear is much worse than the reality, likely stoked by shorts trying to scare out longs. x.comÂ
Significant discounts to broader pharmaceutical industry valuations on projected 2031 earnings make some high-quality mid-cap biotech stocks attractive. Many have cleared Phase 3 trials or reached more advanced stages, and some may reach profitability without more capital, an advantage if financing tightens. Selling these stocks to chase speculative biotech or large pharma at historically elevated multiples makes little sense. x.comÂ
Small- and mid-cap biotech looks like one of healthcare's more asymmetric setups after a four-year bear market, as AI speeds drug discovery and Big Pharma faces a patent cliff. Over $300B of pharma revenue goes off patent in the next few years, M&A is already ramping hard as pharma hunts for assets, and many small and mid-cap names still trade at reasonable valuations, making them potential takeover targets. x.comÂ
The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com x.com … Show more
